Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.

Tomas Eriksson

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Some case reports have shown that patients suffering from obsessive-compulsive disorder can be effectively treated with anti-androgenic pharmacological agents with various modes of action. The most effective group of such agents is the long-acting analogues of the gonadotropin-releasing hormone. This investigation was undertaken in order to further elucidate the possibility of using such powerful anti-androgenic agents in the treatment of obsessive-compulsive disorder. Six male patients, all suffering from therapy-resistant obsessive-compulsive disorder, were included in a 48 weeks open-label trial of the long-acting GnRH-analogue triptorelin. Every other week, the patients rated the severity of obsessive-compulsive disorder symptoms by means of a visual analogue scale. During the course of the trial, five out of six patients experienced a considerable improvement. The finding gives further support to the contention that anti-androgenic agents are effective in the treatment of obsessive-compulsive disorder.
    Original languageEnglish
    Pages (from-to)57-61
    JournalInternational Clinical Psychopharmacology
    Volume22
    Issue number1
    DOIs
    Publication statusPublished - 2007

    Subject classification (UKÄ)

    • Psychiatry

    Free keywords

    • clinical trial
    • anti-androgens
    • gonadotropin-releasing hormone
    • obsessive-compulsive disorder
    • treatment
    • triptorelin

    Fingerprint

    Dive into the research topics of 'Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.'. Together they form a unique fingerprint.

    Cite this